About BriaCell Therapeutics
BriaCell Therapeutics is a publicly listed company based in Beverly Hills (United States) founded in 2004. The company has 18 employees. BriaCell Therapeutics offers products and services including Bria-IMT, Bria-OTS, and Bria-OTS+. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is BriaCell Therapeutics Corp. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.
- Headquarters Beverly Hills, United States
- Employees 18
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website briacell.com
- Social LinkedIn X Facebook
- Legal Name Briacell Therapeutics Corp
- Net Profit-$26.52 M (USD)-463.52as on Jul 31, 2025
- EBITDA-$27.31 M (USD)16.36as on Jul 31, 2025
- Latest Funding Round$399.92K (USD), Grant
Sep 2023
- InvestorsHHS
& 4 more
- Employee Count18
Products & Services of BriaCell Therapeutics
BriaCell Therapeutics offers a comprehensive portfolio of products and services, including Bria-IMT, Bria-OTS, and Bria-OTS+.
Targets metastatic breast cancer through immune activation in clinical trials.
Provides off-the-shelf personalized treatment for breast and prostate cancers.
Enhanced version for various cancers, including prostate, via HLA matching.
Funding Insights of BriaCell Therapeutics
- Total Rounds 18
- Last Round Grant — $399,918
- First Round $299,301
(May 2014)
- Investors Count 5
Latest 10 of 18 funding rounds of BriaCell Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $399,918 | Grant | – | – | |
| Aug 2023 | Grant | – | – | ||
| May 2023 | $4M | Post-IPO | – | – | |
| Jun 2021 | $27.2M | Post-IPO | – | – | – |
| Nov 2020 | $265,000 | Post-IPO | – | – | – |
| Sep 2020 | Grant | – | – | ||
| Oct 2019 | $430,002 | Post-IPO | – | – | – |
| Sep 2019 | $451,918 | Post-IPO | – | – | – |
| Sep 2019 | $642,411 | Post-IPO | – | – | – |
| May 2019 | $140,575 | Post-IPO | – | – |
5 investors in total: 4 institutional and 1 angel.
Investors in BriaCell Therapeutics
BriaCell Therapeutics has secured backing from 5 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include HHS, National Cancer Institute and Prevail Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about Prevail Partners' activities. | prevailpartners.com | |||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cancer research is conducted and supported by the institute. | cancer.gov | Bethesda, United States | ||
| wisemanfoundation.org | ||||
JB Jamieson Bondarenko | unknown_fc4ff69690b945cea |
Investor details for BriaCell Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BriaCell Therapeutics
19 people are tracked at BriaCell Therapeutics (2 in leadership, 12 in board & advisors, 5 in team); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
Miguel A. Lopez-Lago | Senior Director of Research & Development | Leadership |
William V. Williams | President & CEO | Leadership |
Marc Lustig | Director | Board & advisors |
Thomas Kieber-Emmons | Scientific Advisor | Board & advisors |
Doug Faller | Scientific Advisor | Board & advisors |
Charles L. Wiseman | Co-Founder & Principal Advisor | Board & advisors |
Brian Metcalf | Scientific Advisor | Board & advisors |
Cara L. Haymaker | Scientific Advisor | Board & advisors |
Jane A. Gross | Director | Board & advisors |
Jamieson Bondarenko | Chairman | Board & advisors |
Martin E. Schmieg | Director | Board & advisors |
Rebecca Taub | Director | Board & advisors |
Alexander Kharazi | Scientific Advisory Board Member | Board & advisors |
Vaughn C. Embro-Pantalony | Director | Board & advisors |
Pravin Kesarwani | Principal Scientist | Team |
Xiaoyi Zheng | Scientist | Team |
MARCELA SALGADO MD, CCRP | Clinical Development/operations Lead | Team |
Vikas Bhardwaj, Ph.D | Principal Scientist | Team |
SAGARIKA PACHHAL | Associate Scientist | Team |
Complete people profiles for BriaCell Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of BriaCell Therapeutics
BriaCell Therapeutics is a publicly listed company on the TSX with ticker symbol BCT in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Dec 2021
- Listed onTSX: BCT
- Listed entityBriaCell Therapeutics Corp
- Exchange sectorHealth technology
- ISINCA1079303071
- Share price5.31 CAD (-5.35% on the day) · 2026-10-13
- Market capitalisation46,195,869.00 CAD
- EPS (diluted, trailing year)-16.87 CAD
- Volume (last session)4,304
Financials of BriaCell Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -36.7M CAD | -37.8M CAD | |
| 2024 | -6.5M CAD | -45.2M CAD | |
| 2023 | -27.2M CAD | -31.2M CAD | |
| 2022 | -34.1M CAD | -19.4M CAD | |
| 2021 | -17.6M CAD | -8.9M CAD |
Detailed financial statements for BriaCell Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BriaCell Therapeutics
4 dated milestones of BriaCell Therapeutics across 19 years, from founding to its latest funding, stage changes and deals.
- Founded BriaCell Therapeutics is founded.
- Funding First funding round of $299K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $400K.
Competitors of BriaCell Therapeutics
BriaCell Therapeutics has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of BriaCell Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BriaCell Therapeutics
The website of BriaCell Therapeutics (briacell.com) receives about 8.1K visits a month and ranks #2,386,302 among all websites worldwide, #3,267 in Biotechnology and Pharmaceuticals.
- Monthly visits8.1K
▲ 33.1% vs previous month
- Unique visitors2.7K
per month
- Global rank#2,386,302
among all websites
- Category rank#3,267
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit4.0
- Average visit1 min 03 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with BriaCell Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hhmi.org | 100% | 426.7K | #102,183 | View details | |
| uncmedicalcenter.org | 100% | #420,831 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as BriaCell Therapeutics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Briacell Therapeutics
Complete news archive for BriaCell Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BriaCell Therapeutics
BriaCell Therapeutics was founded in 2004 and raised its 1st funding round 10 years after it was founded.
BriaCell Therapeutics is headquartered in Beverly Hills, United States. It is registered at Beverly Hills, California, United States.
BriaCell Therapeutics has 18 employees.
Developer of immunotherapies for the treatment of cancer. Its lead product candidate, Bria-IMT is a genetically engineered whole-cell vaccine derived from a human breast cancer cell line. Bria-IMT is used in combination with multiple immune modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells. Another product Bria-OTS is shelf-personalized immunotherapy for the treatment of advanced-stage breast cancer.
BriaCell Therapeutics's top competitors include C4 Therapeutics, Erasca and MiRagen.
BriaCell Therapeutics offers Bria-IMT, Bria-OTS, and Bria-OTS+.
Yes, BriaCell Therapeutics is publicly traded on TSX under the ticker symbol BCT.
BriaCell Therapeutics has 5 investors. Key investors include HHS, National Cancer Institute, Prevail Partners, Wiseman Cancer Research Foundation, and Jamieson Bondarenko.
BriaCell Therapeutics operates through Briacell Therapeutics Corp..